Wellington Management Group LLP Has $1.08 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Wellington Management Group LLP grew its position in Aura Biosciences, Inc. (NASDAQ:AURA) by 12.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 131,054 shares of the company’s stock after purchasing an additional 14,662 shares during the period. Wellington Management Group LLP owned about 0.26% of Aura Biosciences worth $1,077,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aura Biosciences during the fourth quarter worth about $87,000. AlphaQuest LLC acquired a new stake in shares of Aura Biosciences in the 4th quarter valued at about $136,000. Intech Investment Management LLC bought a new stake in shares of Aura Biosciences in the fourth quarter valued at about $172,000. American Century Companies Inc. boosted its position in shares of Aura Biosciences by 33.9% during the fourth quarter. American Century Companies Inc. now owns 47,701 shares of the company’s stock worth $392,000 after buying an additional 12,081 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Aura Biosciences by 107.5% during the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock worth $477,000 after buying an additional 27,718 shares in the last quarter. 96.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 23,045 shares of company stock valued at $177,242 over the last quarter. Insiders own 5.40% of the company’s stock.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA opened at $5.30 on Monday. Aura Biosciences, Inc. has a 52-week low of $4.84 and a 52-week high of $12.38. The company has a market capitalization of $266.19 million, a PE ratio of -3.06 and a beta of 0.43. The company has a fifty day moving average of $6.96 and a 200-day moving average of $8.27.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). On average, equities analysts forecast that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. JMP Securities set a $19.00 price objective on shares of Aura Biosciences in a research note on Wednesday, March 26th. HC Wainwright set a $25.00 target price on Aura Biosciences in a research report on Tuesday, March 25th. Finally, Citigroup reiterated an “outperform” rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $22.75.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.